Skip to main content

Table 1 Demographic characteristics of the patient’s baseline

From: The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial

 

Intervention (N=69)

Control (N=50)

Sex (men), n (%)

38 (54.29)

32 (45.71)

 

Mean (SD)

Age

46.32 (8.11)

52.56(10.26)

BMI

32.18 (4.24)

31.13 (6.05)

SBP

118.19 (11.42)

121.10 (10.11)

DBP

73.55 (10.58)

74.50 (9.05)

FBS

123.78 (26.52)

113.06 (13.15)

HbA1c

6.59 (0.72)

6.63 (0.44)

Insulin level

17.80 (6.70)

12.84 (4.52)